Post-infusion poly(ethylene glycol) surface modification of chimeric antigen receptor (CAR)-engineered T cells and a subcutaneous chemokine-adsorbing hydrogel address cytokine release syndrome and the neurotoxicity side effects of CAR T cell therapy against tumours.
This is a preview of subscription content, log in via an institution to check access.
References
Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Nat. Rev. Immunol. 22, 85–96 (2022).
Lee, D. W. et al. Blood 124, 188–195 (2014).
Norelli, M. et al. Nat. Med. 24, 739–748 (2018).
Giavridis, T. et al. Nat. Med. 24, 731–738 (2018).
Choy, E. H. et al. Nat. Rev. Rheumatol. 16, 335–345 (2020).
Park, J. H. et al. N. Engl. J. Med. 378, 449–459 (2018).
Gong, N. et al. Nat. Mater. https://doi.org/10.1038/s41563-023-01646-6 (2023).
Li, X. et al. Nat. Biomed. Eng. https://doi.org/10.1038/s41551-023-01084-4 (2023).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
K.S. owns equity in and is a member of the Board of Directors of AMASA Therapeutics, a company developing stem cell-based therapies for cancer. K.S.’s interests were reviewed and are managed by Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict-of-interest policies. C.L. declares no competing interests.
Rights and permissions
About this article
Cite this article
Liu, C., Shah, K. Taming CAR T cell therapy toxicity. Nat. Mater. 22, 1444–1445 (2023). https://doi.org/10.1038/s41563-023-01742-7
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41563-023-01742-7
- Springer Nature Limited